YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
(RTTNews) - Bicycle Therapeutics (BCYC) reported financial results for the second quarter that ended on June 30, 2026, reflecting a narrower net loss and provided updates on the progress of its oncology pipeline. Company Profile Bicycle Th…
Tarsus Pharmaceuticals, Inc. (TARS) shares ended the last trading session 7.5% higher at $65.44. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's…
Tarsus Pharmaceuticals, Inc. (TARS) shares ended the last trading session 7.5% higher at $65.44. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's…
(RTTNews) - Kymera Therapeutics, Inc. (KYMR), a clinical-stage biopharmaceutical company, announced the appointment of Felix J. Baker as Chairman of the Board of Directors. He succeeds Bruce Booth, who has served as Chairman of Kymera sinc…
European equities traded in the US as American depositary receipts were tracking higher late Tuesday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
European equities traded in the US as American depositary receipts were trending slightly higher lat PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
European equities traded in the US as American depositary receipts were trending marginally higher l PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Is GILD a good stock to buy? We came across a bullish thesis on Gilead Sciences, Inc. on Trevor Young’s Substack. In this article, we will summarize the bulls’ thesis on GILD. Gilead Sciences, Inc.'s share was trading at $135.87 as of Apri…
We recently compiled a list of the 10 Best Biotech Stocks Under $10 to Buy. Bicycle Therapeutics plc is one of the best biotech stocks on this list. TheFly reported on April 8 that Morgan Stanley reduced its price target on BCYC to $12 fro…
European equities traded in the US as American depositary receipts began the week little changed lat PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Bicycle Therapeutics plc (NASDAQ:BCYC) is one of the 7 Fastest Growing European Stocks to Invest In. On March 18, 2026, RBC Capital lowered the price target on Bicycle Therapeutics plc (NASDAQ:BCYC) to $7 from $11 and maintained a Sector P…
European equities traded in the US as American depositary receipts were sharply higher late Wednesda PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Enliven Therapeutics Inc. (NASDAQ:ELVN) is one of the 10 Stocks Investors Are Buying Now. Enliven Therapeutics soared to a new five-year high on Wednesday, as investors took heart from two analysts’ optimistic coverage for the stock, with…
European equities traded in the US as American depositary receipts were sharply lower late Friday mo PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Bicycle Therapeutics (NASDAQ:BCYC) is one of the best get-rich-quick stocks to buy according to hedge funds. On February 3, Bicycle Therapeutics announced several key leadership transitions as the company enters a new phase of innovation f…
European equities traded in the US as American depositary receipts were tracking slightly lower late PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
European equities traded in the US as American depositary receipts were tracking higher late Wednesd PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
European equities traded in the US as American depositary receipts were tracking higher late Friday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium ne…
European equities traded in the US as American depositary receipts were on the rise late Thursday mo PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
European equities traded in the US as American depositary receipts were modestly higher late Thursda PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
European equities traded in the US as American depositary receipts were trending lower late Wednesda PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Savvy investors do not always chase expensive stocks to find high-growth opportunities. In fact, some of the most exciting plays in the market trade lower than $10, offering investors the chance to multiply their money over time if the und…
Roger Dansey, M.D., formerly Pfizer and Seagen, and Hervé Hoppenot, of Incyte and formerly Novartis Oncology, bring extensive drug development and commercialization expertise CAMBRIDGE, England & BOSTON, September 08, 2025--(BUSINESS WIRE)…
Bicycle Therapeutics plc (NASDAQ:BCYC) is one of the Top 10 Stocks Under $10 That Could Triple. On August 11, RBC Capital increased its price target on Bicycle Therapeutics plc (NASDAQ:BCYC) from $25 to $27 and kept an Outperform rating af…
* Bicycle Therapeutics press release [https://seekingalpha.com/pr/20194725-bicycle-therapeutics-reports-recent-business-progress-and-second-quarter-2025-financial] (NASDAQ:BCYC [https://seekingalpha.com/symbol/BCYC]): Q2 GAAP EPS of -$1.14…
We recently published a list of Top 11 Small Cap Stocks to Buy with Biggest Upside Potential. In this article, we are going to take a look at where Bicycle Therapeutics plc (NASDAQ:BCYC) stands against other top small cap stocks to buy wit…
Barclays lowered the firm’s price target on Bicycle Therapeutics (BCYC) to $15 from $40 and keeps an Overweight rating on the shares following the Q1 report. The firm says the company’s pipeline catalysts remain on track. “Out of an abunda…
It's been a good week for Bicycle Therapeutics plc (NASDAQ:BCYC) shareholders, because the company has just released its latest full-year results, and the shares gained 8.6% to US$23.98. Revenues of US$27m came in 9.7% below estimates, but…
Bicycle Therapeutics (NASDAQ:BCYC) Full Year 2023 Results Key Financial Results Revenue: US$27.0m (up 87% from FY 2022). Net loss: US$180.7m (loss widened by 60% from FY 2022). US$5.08 loss per share (further deteriorated from US$3.80 loss…
Catalyst-rich 2024 with multiple clinical data readouts and updates expected for pipeline and discovery programs Phase 2/3 Duravelo-2 registrational trial for BT8009 in metastatic urothelial cancer now active and recruiting patients BT8009…
CAMBRIDGE, England & BOSTON, February 07, 2024--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®)…
In this article, we will take a look at the 15 small-cap stocks with high potential. To skip our analysis of the latest trends, and market activity, you can go directly to see the 5 Small-Cap Stocks with High Potential. Nearly 9,500 stocks…
On January 3, 2024, CEO Kevin Lee sold 8,703 shares of Bicycle Therapeutics PLC (NASDAQ:BCYC), according to a recent SEC Filing. This transaction is part of a series of insider sales over the past year, with the insider having sold a total…
Nectin-4 portfolio comprised of BT8009 and BT7480 represents potential opportunity to become leader in treating Nectin-4-driven cancers, starting with metastatic urothelial cancer (mUC) Updated BT8009 clinical data continue to support prom…
CAMBRIDGE, England & BOSTON, November 30, 2023--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®)…
One thing we could say about the analysts on Bicycle Therapeutics plc (NASDAQ:BCYC) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the organization. This report focused on…